#Novonordiskasb

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.

Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US initial public offering.